California State Teachers Retirement System raised its position in shares of CryoLife Inc. (NYSE:CRY) by 22.3% during the second quarter, Holdings Channel reports. The firm owned 66,083 shares of the company’s stock after buying an additional 12,045 shares during the period. California State Teachers Retirement System owned approximately 0.19% of CryoLife worth $780,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the stock. Essex Investment Management Co. LLC acquired a new stake in CryoLife during the second quarter worth about $921,000. Royce & Associates LP boosted its stake in CryoLife by 10.6% in the first quarter. Royce & Associates LP now owns 731,200 shares of the company’s stock worth $7,860,000 after buying an additional 70,000 shares during the period. Spark Investment Management LLC boosted its stake in CryoLife by 217.6% in the first quarter. Spark Investment Management LLC now owns 39,700 shares of the company’s stock worth $426,000 after buying an additional 27,200 shares during the period. BlackRock Fund Advisors boosted its stake in CryoLife by 1.1% in the first quarter. BlackRock Fund Advisors now owns 1,642,615 shares of the company’s stock worth $17,658,000 after buying an additional 18,349 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its stake in CryoLife by 16.3% in the second quarter. Candriam Luxembourg S.C.A. now owns 100,000 shares of the company’s stock worth $1,181,000 after buying an additional 14,000 shares during the period. Hedge funds and other institutional investors own 58.13% of the company’s stock.
CryoLife Inc. (NYSE:CRY) traded up 0.92% during trading on Friday, hitting $17.57. 359,344 shares of the stock were exchanged. The firm’s 50 day moving average price is $16.79 and its 200-day moving average price is $13.23. CryoLife Inc. has a 1-year low of $8.94 and a 1-year high of $18.64. The stock has a market cap of $599.31 million, a price-to-earnings ratio of 56.31 and a beta of 1.14.
CryoLife (NYSE:CRY) last posted its earnings results on Monday, July 25th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.11. CryoLife had a return on equity of 8.15% and a net margin of 5.80%. The business earned $47.10 million during the quarter, compared to analysts’ expectations of $35.50 million. During the same period in the prior year, the business earned $0.03 EPS. CryoLife’s revenue for the quarter was up 32.6% compared to the same quarter last year. On average, analysts anticipate that CryoLife Inc. will post $0.34 EPS for the current year.
CRY has been the subject of a number of analyst reports. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $16.00 target price on shares of CryoLife in a research note on Wednesday, July 27th. Lake Street Capital initiated coverage on shares of CryoLife in a research note on Wednesday, June 15th. They issued a “buy” rating and a $15.00 target price for the company. Canaccord Genuity reiterated a “buy” rating on shares of CryoLife in a research note on Monday, June 20th. Finally, Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “strong-buy” rating and set a $18.00 target price for the company in a research note on Friday, August 12th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. CryoLife presently has a consensus rating of “Buy” and an average target price of $15.00.
In related news, Director C Elkins Ronald sold 2,000 shares of the stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total transaction of $28,000.00. Following the completion of the sale, the director now directly owns 103,586 shares of the company’s stock, valued at approximately $1,450,204. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 6.08% of the company’s stock.
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.